Dermira to Present at Upcoming Investor Conferences in November
09 nov. 2017 17h36 HE
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis
06 nov. 2017 16h03 HE
|
Dermira, Inc.
- FDA decision on New Drug Application expected by June 30, 2018 - Licensed exclusive, worldwide rights to lebrikizumab from Roche - Completed patient enrollment in two Phase 3 trials for the...
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
06 nov. 2017 16h01 HE
|
Dermira, Inc.
Dermira to transition development and commercialization responsibility for CIMZIA® (certolizumab pegol) in psoriasis back to UCBDecision reflects both companies’ strategic prioritiesUCB remains...
Dermira Highlights New Long-Term Safety Data for Glycopyrronium Tosylate in Primary Axillary Hyperhidrosis at Fall Clinical Dermatology Conference
13 oct. 2017 08h00 HE
|
Dermira, Inc.
- Daily treatment with glycopyrronium tosylate in the Phase 3, open-label ARIDO trial was generally well-tolerated during 44 weeks of treatment- Efficacy assessment suggests sweat reduction levels...
Dermira Completes Patient Enrollment in Two Phase 3 Pivotal Trials of Olumacostat Glasaretil for the Treatment of Acne Vulgaris
05 oct. 2017 08h00 HE
|
Dermira, Inc.
- Phase 3 pivotal trials enrolled a total of 1,503 patients- Topline efficacy and safety results expected in first quarter of 2018 MENLO PARK, Calif., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Dermira,...
Dermira to Present at Cantor Fitzgerald Global Healthcare Conference
20 sept. 2017 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Early Termination of the Hart-Scott-Rodino Waiting Period for License to Lebrikizumab
14 sept. 2017 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
New CIMZIA® (certolizumab pegol) Findings Presented at European Academy of Dermatology and Venereology (EADV) Congress
14 sept. 2017 08h00 HE
|
Dermira, Inc.
Presentations included the first 48-week data from the CIMPASI-1 and CIMPASI-2 psoriasis trials, and re-randomized data through 48 weeks from the CIMPACT psoriasis trial 1,2Treatment with CIMZIA was...
Dermira Presents New Data Showing Impact of Primary Axillary Hyperhidrosis on Patients
13 sept. 2017 08h00 HE
|
Dermira, Inc.
People suffering from primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed to maintain normal body temperature) report that the condition has a significant impact on their...
Dermira Presents New Data on Late-Stage Programs at Leading European Dermatology Congress
07 sept. 2017 07h30 HE
|
Dermira, Inc.
New findings from the glycopyrronium tosylate Phase 3 program highlight potential benefits of the investigational treatment and the impact of primary axillary hyperhidrosis on patients’ daily...